Iqvia (NYSE:IQV) Raised to “Buy” at Mizuho

Mizuho upgraded shares of Iqvia (NYSE:IQV) from a neutral rating to a buy rating in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has $175.00 price objective on the medical research company’s stock, up from their prior price objective of $150.00.

Several other research firms have also commented on IQV. Argus lifted their price target on Iqvia from $140.00 to $160.00 and gave the stock a buy rating in a research report on Monday, February 25th. They noted that the move was a valuation call. Stifel Nicolaus upped their price objective on Iqvia from $167.00 to $178.00 and gave the stock a buy rating in a report on Wednesday, June 19th. William Blair reiterated an outperform rating on shares of Iqvia in a research report on Wednesday, June 19th. Leerink Swann assumed coverage on Iqvia in a research report on Tuesday, May 28th. They set an outperform rating and a $136.38 target price on the stock. Finally, Barclays upped their price objective on Iqvia from $160.00 to $167.00 and gave the company an overweight rating in a research report on Monday, March 18th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. Iqvia has an average rating of Buy and an average target price of $153.65.

Shares of NYSE:IQV opened at $158.67 on Friday. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market cap of $31.30 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 1.92 and a beta of 0.77. Iqvia has a 12-month low of $97.64 and a 12-month high of $159.54.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.12. The business had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.34 EPS. On average, sell-side analysts forecast that Iqvia will post 5.89 EPS for the current year.

In other Iqvia news, insider Kevin C. Knightly sold 46,080 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $138.06, for a total transaction of $6,361,804.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael J. Evanisko sold 1,193 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. Insiders have sold 143,273 shares of company stock worth $20,934,730 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. C J Advisory Inc bought a new position in Iqvia during the first quarter worth $27,000. Baystate Wealth Management LLC purchased a new position in Iqvia in the first quarter valued at about $27,000. Parkside Financial Bank & Trust boosted its stake in Iqvia by 140.2% in the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 122 shares during the last quarter. Berman Capital Advisors LLC bought a new stake in Iqvia during the 4th quarter worth approximately $46,000. Finally, ERTS Wealth Advisors LLC bought a new position in shares of Iqvia in the 4th quarter worth $46,000. Institutional investors and hedge funds own 89.69% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit